Bong-Joon Kim
Inhibitors of Sodium Glucose Co-transporter 2 (SGLT-2) reduce the risk of hospitalization for heart failure. Recent studies showed evidence supporting the effects of SGLT-2 inhibitors on broad spectrum of Heart Failure (HF) regardless of left ventricular ejection fraction. There have been many changes in the guideline if HF and several studies of SGLT-2 have played a key role.
In stable outpatients HF patients, the event such as cardiovascular death or HF hospitalization is less likely to occur. So, intensification of diuretic therapy also is a representative indicator of worsening HF. The current study’s objective was to examine the effect of SGLT-2 inhibitors on change of diuretics dose in outpatient HF patients.